Kyverna Therapeutics EBIT

The latest EBIT for KYTX is $-160M as of March 2026. That compares with $-160M in the prior-year period — down 3.0% year over year. That is below the sector sector average of $-69M. Investors often review this figure alongside Kyverna Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, KYTX's EBIT moved from $-160M to $-160M — a 3.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Kyverna Therapeutics's operating scale or balance-sheet position.

Against its sector companies, KYTX currently prints $-160M for EBIT, while the sector average sits near $-69M. That is roughly 134.5% below the sector mean. Large gaps often invite a closer look at Kyverna Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $-160M for KYTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-69M. Explore the charts below for those layers of context.

After noting KYTX's EBIT ($-160M), review year-over-year change from $-160M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.